EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantification of the synergism between HER-targeted drugs with human blood serum and EGF

D E Kamashev, E M Leboshchina, A V Koleboshina, I A Lavrinenko, G A Vashanov, Yu D Nechipurenko

Acta Naturae · 22.04.2026 · 18 (1) · 46-54

DOI: 10.32607/actanaturae.27649 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Naturae, online erschienen am 22.04.2026. Verfasst von D E Kamashev und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, 117997 Russia. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Finding the optimal combination of drugs for the effective inhibition of cancer cell growth is an extremely important task today, as the number of such drugs continues to grow. There are several approaches to determining the nature of drug interactions, allowing one to establish whether they are additive, synergistic, or antagonistic. One such approach is described here, and it is demonstrated how to quantitatively measure the degree of interaction between two drugs. It is shown that human peripheral blood serum and EGF modulate the activity of HER2-targeted drugs in inhibiting the proliferation of HER2-positive BT474 and SK-BR-3 cells. We compared the effect of blood serum samples from breast cancer (BC) patients and healthy donors on the action of trastuzumab. Using the proposed method, it is possible to calculate the Combination Index (CI). For 17 serum samples from healthy donors, the mean CI was 0.396, while for 19 serum samples from patients with BC, the mean CI was 0.214. These results indicate a synergistic interaction between trastuzumab and blood serum in both groups. We also found significant differences in CI values between healthy donors and breast cancer patients: blood serum samples from patients enhance the effect of trastuzumab to a greater extent.

Schlagwörter

Stichwörter der Autor:innen

HER2breast cancerhuman blood serumlapatinibtargeted therapytrastuzumab

Autor:innen und Institutionen

  • Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, 117997 Russia.
  • World-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, Moscow, 119991 Russia.
  • Moscow Institute of Physics and Technology, Dolgoprudny, 141701 Russia.
  • Voronezh State University, Voronezh, 394018 Russia.
  • Engelhardt Institute of Molecular Biology, Moscow, 119991 Russia.

Zitieren

APA

Kamashev, D. E., Leboshchina, E. M., Koleboshina, A. V., Lavrinenko, I. A., Vashanov, G. A., & Nechipurenko, Y. D. (2026). Quantification of the synergism between HER-targeted drugs with human blood serum and EGF. Acta Naturae, 18(1), 46-54. https://doi.org/10.32607/actanaturae.27649

Vancouver

Kamashev DE, Leboshchina EM, Koleboshina AV, Lavrinenko IA, Vashanov GA, Nechipurenko YD. Quantification of the synergism between HER-targeted drugs with human blood serum and EGF. Acta Naturae. 2026;18(1):46-54. doi:10.32607/actanaturae.27649

BibTeX
@article{Kamashev2026,
  author = {Kamashev, D E and Leboshchina, E M and Koleboshina, A V and Lavrinenko, I A and Vashanov, G A and Nechipurenko, Yu D},
  title = {Quantification of the synergism between HER-targeted drugs with human blood serum and EGF},
  journal = {Acta Naturae},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {46--54},
  doi = {10.32607/actanaturae.27649}
}
Kostenlos starten →